Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

PG Soft Releases Anime-Inspired Oishi Delights

PG Soft, a world-class digital mobile games company, has released its Japanese-inspired slot, Oishi Delights.PG Soft’s Asian adventure transpires within a bright and celebratory festival atmosphere, surrounded by grand pagodas. The game sits within a 5-reel, 8-row layout featuring multipliers reaching as high as x1024. The Wild symbol substitutes for all symbols except for the Scatter symbol and only appears on reels two, three, and four. Wind chime symbols, aside from the Wild and Scatter symbol, can emerge to cover a space spanning three symbols within reels two, three and four.

Minutes of extraordinary general meeting

held in DanCann Pharma A/S, CVR-no. 39 42 60 05 (“Company”)(Please note: The capital reduction (item 1) and the resulting amendments of the articles of association cannot be completed before expiration of the 4-week notice period (“proklama”) which commences today. Attached are updated articles of association without the capital reduction (effective today) and updated articles of association including the capital reduction). On 7 October 2024 at 09:00 am (CET), an extraordinary general meeting was held in the Company at the Company’s address, Rugvænget 5, 6823 Ansager, Denmark.

Form 8.3 - Anglogold Ashanti Plc

FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   +--------------------------------------------------------+---------------------+|(a) Full name of discloser: |Ninety One UK Ltd |+--------------------------------------------------------+---------------------+|(b) Owner or controller of interests and short positions|  ||disclosed, if different from 1(a):

IFS strengthens Executive Board with CIO and CHRO appointments

Helena Nimmo appointed CIO and Debra McCowan appointed CHRO to fuel IFS’s next phase of growth in pioneering and dominating Industrial AILondon, October 7, 2024 – IFS, the leading provider of enterprise cloud and Industrial AI software, has made two senior appointments to its Executive Board. Helena Nimmo joins as global Chief Information Officer (CIO) and Debra McCowan as Chief Human Resources Officer (CHRO). Nimmo joins from Endava, a US-listed global technology company with over 12,000 employees. As CIO at IFS, Nimmo will engage CIOs and tech leaders at IFS customers to

Fredrik Aaben new CFO of Enviro

Scandinavian Enviro Systems (Enviro) has appointed Fredrik Aaben as new CFO. Fredrik Aaben joins Enviro from his role of Head of Corporate Finance at Volvo Cars, where he has a long-standing background of managerial positions in finance, M&A and strategy. Fredrik Aaben, new CFO of Enviro. Aaben will take up his position in November 2024 and will work in parallel with the current interim CFO Christian Bergaust for a transitional period. Aaben has a long-standing background at Volvo Cars that has included developing the company’s Corporate Finance department and, as Head of

Brain+ announces first day of trading in new shares from the TO 4 warrant exercise and the related directed issue

Copenhagen, Denmark, 7 October 2024– Brain+ A/S (Nasdaq First North: BRAINP) On 1 October 2024, Brain+ A/S (“Brain+” or “the Company”) announced that 38,522,165 of its warrants of series TO4 (the ‘Warrants’) had been exercised for subscription of 38,522,165 new shares and the decision to carry out a directed issue of 2,517,179 new shares to guarantors of the Warrant exercise (the “Directed Issue”). The TO 4 warrants were issued in connection with Brain+’ unit rights issue in June 2024. The new shares from both the Warrant exercise and the Directed Issue have now been registered with the

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 222 – 7 OCTOBER 2024   In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 171/24 and 173/24, respectively. Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Martin Badsted, Chief Financial Officer, tel.: +45 33 42 05 26, e-mail: mba@norden.com

Buyback of Class B shares in Essity during week 40, 2024

Between September 30, 2024, and October 4, 2024, Essity Aktiebolag (publ) repurchased a total of 270,000 own Class B shares (ISIN: SE0009922164) under the framework of the buyback program as resolved by the Board of Directors.The share purchase is part of the SEK 3bn buyback program announced by Essity on June 17, 2024. The buyback program will extend from June 17, 2024, until the 2025 Annual General Meeting and be implemented in accordance with the EU Market Abuse Regulation (MAR) and the European Commission’s Delegated Regulation 2016/1052 (Safe Harbour Regulation). The share

Dampskibsselskabet NORDEN A/S – weekly report on share buy-back

ANNOUNCEMENT NO. 221 – 7 OCTOBER 2024   On 9 August 2024, NORDEN initiated a share buy-back programme in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buy-back programme runs from 9 August 2024 up to and including no later than 23 October 2024. For details, please see announcement no. 171 of 8 August 2024.   Under the share buy-back programme, NORDEN will purchase shares for up to a total of USD 14 million (approximately DKK 95 million).

Report of transactions in TORM plc securities by directors and executive officers and their closely associated persons

TORM plc has been notified of the following transactions in TORM plc securities:   +---------------------------------------+--------+------------------+|Details of the reporting person / closely associated person |+---------------------------------------+--------+------------------+|Name |Göran Trapp |+---------------------------------------+--------+------------------+|Reason for the notification |+---------------------------------------+--------+------------------+|Position/

Invitation presentation of Boliden’s Q3 2024 report

Boliden will announce its Interim Report for the third quarter 2024 on Tuesday, October 22, at 07:45 (CEST). A press and analyst conference will be held on the same day at 09:30, which also can be followed via webcast and telephone. The report will be presented by Boliden’s President and CEO Mikael Staffas, and CFO Håkan Gabrielsson. Press and analyst conference Tuesday, October 22Time:              09.30 (CEST)Venue:            Klara, Room DagermanAddress:         Klarabergsviadukten 90, Stockholm To participate via the webcast, please use the link below: https://boliden.

Buybacks of shares by H&M during week 40, 2024

Between 30 September 2024 and 4 October 2024 H & M Hennes & Mauritz AB (publ) (LEI code 529900O5RR7R39FRDM42) has repurchased in total 698,042 own B shares (ISIN: SE0000106270) as part of the share buyback programme initiated by the board of directors. The share buybacks form part of the SEK 1 billion share buyback programme that H&M announced on 26 September 2024. The share buyback programme, which runs between 26 September 2024 and no later than 26 November 2024, is being carried out in accordance with Regulation (EU) No 596/2014 on market abuse (the Market Abuse Regulation – MAR) and

AstraZeneca licenses lipid lowering Lp(a) asset

7 October 2024 AstraZeneca strengthens its cardiovascular pipeline with agreement for a pre-clinical novel lipid-lowering therapy AstraZeneca has entered into an exclusive license agreement with CSPC Pharmaceutical Group Ltd (CSPC) to advance the development of an early stage, novel small molecule Lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidaemia. This asset further strengthens the company's cardiovascular portfolio to help address the major risk factors driving chronic cardiovascular disease.   Under the terms of

Invitation: Kemira to publish January–September 2024 results on October 25, 2024

Kemira Oyj, Press Release, October 7, 2024 at 11.30 am (EEST)Invitation: Kemira to publish January–September 2024 results on October 25, 2024 Kemira Oyj will publish its January–September 2024 results on Friday, October 25, 2024 at around 8.30 am Finnish time (6.30 am UK time). Webcast for analysts, investors, and media will be held on Friday, October 25, 2024 starting at 10.30 am (8.30 am UK time). At the webcast, Kemira’s President and CEO Antti Salminen and CFO Petri Castrén will present the results. The webcast will be held in English and can be followed at kemira.com/investors (

Moldova Receives 'B+' Rating with Stable Outlook from Fitch Ratings, Signaling Economic and Financial Resilience

Fitch Ratings has assigned the Republic of Moldova a Long-Term Foreign-Currency Issuer Default Rating (IDR) of 'B+' with a Stable Outlook . This rating highlights the country’s steady commitment to maintaining macroeconomic and financial stability through prudent fiscal policies, a credible inflation-targeting framework, and a flexible exchange rate regime. These factors,

Immunovia has successfully acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer

LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer. Concluding the sample collection effort marks a key milestone toward successfully completing the clinical validation study.  The study seeks to confirm the sensitivity and specificity reported previously in the company’s model-development study of its new test. The trial will be a case-control study evaluating the accuracy of the next-generation test

Supplement to the Release: Inside Information: Musti Group to acquire Pet City OÜ (Pet City) from Magnum Group

Musti Group plc           Stock Exchange Release    7 October 2024 at 11.05 a.m.   Supplement to the Release: Inside Information: Musti Group to acquire Pet City OÜ (Pet City) from Magnum Group   Musti Group plc supplements the Company release published on October 7th at 9.30 am EEST with the information that the acquisition will be settled in cash and provides additional financial information reflecting the financial position of Pet City OÜ.   The original release including supplemental information regarding Pet City OÜ (including its subsidiaries Eesti Veterinaaria

Fear of childbirth is associated with shorter duration of breastfeeding

The duration of breastfeeding is shorter than average among mothers with a fear of childbirth – regardless of the mode of delivery, a new study from Finland shows. According to the researchers, the fear of childbirth can also be an indication of a greater need for breastfeeding support. Using data from the Kuopio Birth Cohort study, KuBiCo, the study examined factors related to childbirth that may affect the success and duration of breastfeeding in the child’s first year of life. The researchers analysed data collected in 2013–2020, which included 2,521 women who had given birth in

Hansa Biopharma’s HNSA-5487 Achieved Rapid and Highly Robust IgG Reduction by More Than 95% and Clear Redosing Potential in First-in-Human Trial

Lund, Sweden, 7 October 2024. Hansa Biopharma AB, (“Hansa” or the “Company”) (Nasdaq Stockholm: HNSA), today announced positive results from a 12-month follow up analysis from the NICE-01 trial of HNSA-5487, the Company’s next generation immunoglobulin G (IgG)-cleaving molecule, assessing IgG recovery, immunogenicity and redosing potential. In the NICE-01 trial, HNSA-5487 demonstrated rapid and highly robust reduction of IgG levels by more than 95 percent within a few hours post treatment. In a 12-month follow up analysis IgG levels returned to normal range six months after initial

UPM Raflatac Helps Enhance Packaging Recyclability with New Labels Guide E-Book

(UPM, Helsinki, 7 October 2024 at 11:00 EEST) – UPM Raflatac is pleased to announce the launch of its new Packaging Recyclability Guide, designed to help fast-moving consumer goods (FMCG) stakeholders across the packaging value chain navigate the complexities of packaging design and recyclability. The new guide, which is available as a free e-book on the company’s website here  or as a downloadable pdf here , offers practical information on the guidelines,

NIB and Epiroc agree on sustainability-linked financing

The Nordic Investment Bank (NIB) and Epiroc AB, the Sweden-based global mining and construction equipment manufacturer and service provider, have signed a ten-year USD 150 million (approx. EUR 136 million) sustainability-linked loan. The loan is connected to Epiroc’s climate targets, which support the decarbonisation of the mining industry.Epiroc aims to significantly reduce absolute carbon emissions from its operations and the use of its sold products, as well as to transform its product offering to include a full range of emission-free alternatives by 2030. The targets related to its own

AFRY selected as a main engineering partner for SSAB’s fossil-free steel project in Sweden

SSAB, a global specialised steel company, has awarded AFRY the main engineering partner contract for their fossil-free steel mini-mill project in Luleå, Sweden. AFRY’s assignment includes basic and detail engineering. The services will be provided during 2024-2026.SSAB is undertaking a major project to transform to fossil-free steel production. SSAB is planning to replace the current blast furnace production route with a new, state-of-the-art mini-mill concept that utilises electric arc furnaces (EAFs). The mini-mill will produce 2.5 million tonnes of fossil-free steel per year. Once

Thorlabs Mini2P Imaging System Leverages poLight ASA TLens® for Optimal Neurological Imaging

Imaging Workflow System on Display at Neuroscience 2024, Booth #1101HORTEN, Norway – October 7, 2024 -- poLight ASA  (OSE: PLT) today announced that Thorlabs ’ Miniature Two-Photon Imaging System (Mini2P) features the TLens® Silver tunable optics, delivering fast multiplane imaging with a <0.4ms response time in freely moving specimens. Available in two MEMS scanner configurations, the lightweight, head-mounted design allows for hundreds of neurons to be monitored in a single field of

There are no items matching the current filter
There are no more items matching the current filter
Back to top